ADAR1 RNA Deaminase Limits Short Interfering RNA Efficacy in Mammalian Cells*

Weidong Yang‡‡, Qingde Wang‡‡, Kelly L. Howell‡, Joshua T. Lee‡, Dan-Sung C. Cho‡, John M. Murray‡, and Kazuko Nishikura‡‡

From ‡The Wistar Institute, Philadelphia, Pennsylvania 19104, and the ‡‡Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104

Double-stranded RNA induces the homology-dependent degradation of cognate mRNA in the cytoplasm via RNA interference (RNAi) but also is a target for adenosine-to-inosine (A-to-I) RNA editing by adenosine deaminases acting on RNA (ADARs). An interaction between the RNAi and the RNA editing pathways in Caenorhabditis elegans has been suggested recently, but the precise mode of interaction remains to be established. In addition, it is unclear whether this interaction is possible in mammalian cells with their somewhat different RNAi pathways. Here we show that ADAR1 and ADAR2, but not ADAR3, avidly bind short interfering RNA (siRNA) without RNA editing. In particular, the cytoplasmic full-length isoform of ADAR1 has the highest affinity among known ADARs, with a subnanomolar dissociation constant. Gene silencing by siRNA is significantly more effective in mouse fibroblasts homozygous for an ADAR1 null mutation than in wild-type cells. In addition, suppression of RNAi effects are detected in fibroblast cells overexpressing functional ADAR1 but not when overexpressing mutant ADAR1 lacking double-stranded RNA-binding domains. These results identify ADAR1 as a cellular factor that limits the efficacy of siRNA in mammalian cells.

* This work was supported in part by grants from the National Institutes of Health, the Doris Duke Charitable Foundation, the March of Dimes, and the Commonwealth Universal Research Enhancement Program, Pennsylvania Department of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ Both authors contributed equally to this work.

§ To whom correspondence should be addressed: The Wistar Institute, 3601 Spruce St., Philadelphia, PA 19104. Tel.: 215-898-3828; Fax: 215-898-3911; E-mail: kazuko@wistar.upenn.edu.

¶ This paper is available on line at http://www.jbc.org.

1 The abbreviations used are: dsRNA, double-stranded RNA; ADAR, adenosine deaminases acting on RNA; A-to-I, adenosine-to-inosine; GluR, glutamate receptor; mAb, monoclonal antibody; MEF, mouse embryonic fibroblasts; PKR, interferon inducible serine/threonine kinase; RNAi, RNA interference; siRNA, short interfering RNA; EGFP, enhanced green fluorescent protein; FACS, fluorescence-activated cell sorter; RFP, red fluorescent protein; EMSA, electrophoretic mobility shift assay; nt, nucleotide.

2 The expression of the full-length ADAR1 (ADAR1p150) is driven by a yeast GAL1 promoter. ADAR1p150 is found mainly in the cytoplasm, whereas both ADAR1p110 and ADAR2 localize to the nucleus and nucleolus (24–26). Recent proteomic analyses have identified ADAR3 among proteins localized within the nucleoli (27). Both ADAR1 and ADAR2 form a stable, enzymatically active homodimer complex, whereas ADAR3 remains as a monomeric, enzymatically inactive form, indicating that oligomerization may play a role in the site-selective editing mechanism (28).

Because ADARs possess unique enzymatic activity capable of generating multiple I-U mismatched base pairs in dsRNA, it has been suggested that they may suppress RNAi efficacy (6, 29). A-to-I RNA editing of dsRNAs derived from transgenes and

hanges in the sense and antisense strands. Each siRNA is used in multiple rounds of degradation of the target mRNA following integration into the RNA-induced silencing complex (4, 5). Introduction of trigger dsRNAs (usually ≥30 bp) into mammalian cells initiates a series of cellular responses including the induction of interferons, which in turn activate a group of interferon-inducible genes such as PKR (interferon-inducible serine/threonine kinase). PKR catalyzes the phosphorylation of the α subunit of protein synthesis initiation factor 2 (eIF-2α), which leads eventually to a global shutdown of protein synthesis (8). Activation of this nonspecific pathway could mask any sequence-specific effects that might result from the RNAi pathway (4, 5). Nevertheless, successful application of RNAi has been reported in many mammalian tissue culture cell lines by using chemically synthesized siRNAs instead of trigger dsRNAs, thus bypassing activation of PKR (9, 10). However, there may also be factors other than PKR that limit RNAi efficacy in mammalian cells.

ADAR is responsible for site-specific RNA editing of coding sequences (11, 12) and noncoding intron and untranslated region sequences containing inverted repeats such as Alu and L1 elements (13–15). This family of enzymes convert selected adenosine residues into inosine in substrate RNAs containing a relatively short dsRNA region (1, 2). A-to-I RNA editing of coding regions can lead to functional alterations of the affected genes (11, 12), whereas editing of noncoding regions may affect the splicing rate, the translation efficacy, or the stability of the edited mRNAs (13–16). Three separate ADAR gene family members (ADAR1 to ADAR3) have been identified in mammals (Fig. 1) (17–23). In addition, two forms of ADAR1, a full-length 150-kDa form (p150) and a shorter 110-kDa protein (p110), are synthesized via alternative translation initiation codons (24). The ADAR1 mRNA transcribed from an interferon- and dsRNA-inducible promoter directs translation of p150, whereas two other ADAR1 mRNAs transcribed from constitutive promoters direct synthesis of p110 initiated from a downstream methionine codon (24). The transcriptional regulation of ADAR2 and ADAR3 genes are currently unknown. ADAR1p150 is found mainly in the cytoplasm, whereas both ADAR1p110 and ADAR2 localize to the nucleus and nucleolus (24–26). Recent proteomic analyses have identified ADAR3 among proteins localized within the nucleoli (27). Both ADAR1 and ADAR2 form a stable, enzymatically active homodimer complex, whereas ADAR3 remains as a monomeric, enzymatically inactive form, indicating that oligomerization may play a role in the site-selective editing mechanism (28).

Because ADARs possess unique enzymatic activity capable of generating multiple I-U mismatched base pairs in dsRNA, it has been suggested that they may suppress RNAi efficacy (6, 29). A-to-I RNA editing of dsRNAs derived from transgenes and

hanges in the sense and antisense strands. Each siRNA is used in multiple rounds of degradation of the target mRNA following integration into the RNA-induced silencing complex (4, 5). Introduction of trigger dsRNAs (usually ≥30 bp) into mammalian cells initiates a series of cellular responses including the induction of interferons, which in turn activate a group of interferon-inducible genes such as PKR (interferon-inducible serine/threonine kinase). PKR catalyzes the phosphorylation of the α subunit of protein synthesis initiation factor 2 (eIF-2α), which leads eventually to a global shutdown of protein synthesis (8). Activation of this nonspecific pathway could mask any sequence-specific effects that might result from the RNAi pathway (4, 5). Nevertheless, successful application of RNAi has been reported in many mammalian tissue culture cell lines by using chemically synthesized siRNAs instead of trigger dsRNAs, thus bypassing activation of PKR (9, 10). However, there may also be factors other than PKR that limit RNAi efficacy in mammalian cells.

ADAR is responsible for site-specific RNA editing of coding sequences (11, 12) and noncoding intron and untranslated region sequences containing inverted repeats such as Alu and L1 elements (13–15). This family of enzymes convert selected adenosine residues into inosine in substrate RNAs containing a relatively short dsRNA region (1, 2). A-to-I RNA editing of coding regions can lead to functional alterations of the affected genes (11, 12), whereas editing of noncoding regions may affect the splicing rate, the translation efficacy, or the stability of the edited mRNAs (13–16). Three separate ADAR gene family members (ADAR1 to ADAR3) have been identified in mammals (Fig. 1) (17–23). In addition, two forms of ADAR1, a full-length 150-kDa form (p150) and a shorter 110-kDa protein (p110), are synthesized via alternative translation initiation codons (24). The ADAR1 mRNA transcribed from an interferon- and dsRNA-inducible promoter directs translation of p150, whereas two other ADAR1 mRNAs transcribed from constitutive promoters direct synthesis of p110 initiated from a downstream methionine codon (24). The transcriptional regulation of ADAR2 and ADAR3 genes are currently unknown. ADAR1p150 is found mainly in the cytoplasm, whereas both ADAR1p110 and ADAR2 localize to the nucleus and nucleolus (24–26). Recent proteomic analyses have identified ADAR3 among proteins localized within the nucleoli (27). Both ADAR1 and ADAR2 form a stable, enzymatically active homodimer complex, whereas ADAR3 remains as a monomeric, enzymatically inactive form, indicating that oligomerization may play a role in the site-selective editing mechanism (28).

Because ADARs possess unique enzymatic activity capable of generating multiple I-U mismatched base pairs in dsRNA, it has been suggested that they may suppress RNAi efficacy (6, 29). A-to-I RNA editing of dsRNAs derived from transgenes and
ADAR1 RNA Editase Limits siRNAi Efficacy

endogenous genes indeed appears to prevent their silencing by RNAi in Caenorhabditis elegans, revealing one potential inter- 
section of the RNA editing and RNAi pathways and the antag-
monic effects of ADAR in vivo on RNAi (30, 31). In these 
previous studies, the long trigger dsRNA was proposed to be 
the target of ADAR (6, 29–31), but potential direct interactions 
between ADAR and siRNA have never been investigated. In 
the present study, we examined the interaction of ADAR with 
siRNAs. We find that ADAR1p150 binds siRNAs with ex-
tremely high affinity. In addition, our in vivo RNAi experi-
ments conducted with fibroblasts homozygous for an ADAR1 null 
mutation revealed ADAR1 suppression of siRNA-based 
RNAi. We propose cytoplasmic ADAR1p150 as a cellular factor 
limiting siRNA efficacy in mammalian cells.

EXPERIMENTAL PROCEDURES

Oligonucleotides and Synthetic siRNAs—Synthetic RNAs for prepa-
ration of 36- and 29-bp siRNAs or varying sizes of EGFP siRNAs 
corresponding to part of the sense or antisense EGFP-C1 sequence 
(Clontech) were synthesized by the University of Pennsylvania Cancer 
Center Nucleic Acid Facility: 21DNAS1, 5'-CGCAUACAAUUU-3' 
and 21NSA1, 5'-GUCUGCGAU-3'; 17EGFPS1, 5'-UUGAAGAAGUCGUGCUGC-3'; 17EGFPA1, 5'-CGGACU-
GCAGCACGACUUCUUCAAGUCCGUU-3'; 19EGFPS1 and 19EGFPA1; 15-bp siRNA, 17EGFPS1 and 17EGFPA1. 

siRNA or siDNA single strands were phosphorylated in the 
presence of 50 Ci of [32P]ATP (3000 Ci/mmol) (Amersham Biosciences). For some 
experiments, RNA and DNA single strands were phosphorylated in 
the presence of nonradioactive ATP. The combinations of sense and 
antisense strand RNAs or DNAs used for preparation of specific siRNAs or 
siDNAs were as follows: 36-bp siRNA, 38RNAS1 and 38RNAA1; 29-bp 
siRNA, 31RNAS1 and 31RNAA1; 23-bp siRNA, 25EGFPS1 and 
25EGFPF1; 19-bp siRNA, 21EGFPS1 and 21EGFPF1; 19-bp blunt end 
dsRNA, 19EGFPS1 and 19EGFPF1; 15-bp siRNA, 17EGFPS1 and 
17EGFPA1; 17-bp sense-specific antisense DNA, 21NS1S and 
21NS1A; and 19-bp siDNA, 21DSN1S and 21DSN1A.

Recombinant ADAR Proteins—FLAG epitope-tagged ADAR proteins 
(ADAR1p150 and p110, ADAR2, ADAR3, ADAR1p150E912A, and 
ADAR2E2396A) were ectopically expressed in ST9 cells and purified by 
affinity column chromatography using anti-FLAG M2 ab agarose gel 
(Sigma) as described previously (32). The purity of recombinant 
proteins (>95% pure) was monitored by electrophoresis on a 8% SDS-
polyacrylamide gel (40:1; acrylamide:bisacrylamide), pre-run at 4 °C 
for 30 min, in 1× TBE (0.1× Tris, 0.5× H3BO3, 1× mM EDTA). Gels 
were electrophoresed further at 500 V for 3 h. Radioactivity in the dried 
gels was quantitated using a PhosphorImager and the ImageQuant 
software (Molecular Dynamics). The fraction of siRNA bound to 
ADARs was determined by dividing the radioactivity measured in 
the siRNA-ADAR complex band by the radioactivity in the free siRNA 
band. The radioactivity of the smeared material between the siRNA-
ADAR complex and the free siRNA bands was included in the bound 
fraction. Kd was defined as the protein concentration required for 50% 
 binding (32).

Two-dimensional TLC Analysis for siRNA—For analysis of inosine 
modification, RNA samples subjected to complex formation with 
ADAR1p150 (10 nm) or ADAR2 (25 nm) at 30 °C for 60 min were first 
digested to 3' NMPs with RNase T2, phenol/chloroform-, chloroform-
, and ether-extracted, and dried. The 5' ends of lyophilized 3' NMPs 
were then labeled with polynucleotide kinase and 10 μCi of [γ-32P]ATP 
at 37 °C for 30 min; polynucleotide kinase was heat-inactivated at 65 °C 
for 20 min. The resulting 32P-labeled 5'-3'-phospho-mononucleotides 
were then digested to 5'-3'PNMPs with P1 nuclease (5'-phospho-
mononucleoside analysis). As a control, c-myc dsRNA, which had been 
subjected to A-to-I modification by ADAR1p150 (10 nm) at 30 °C for 
60 min, was analyzed in parallel. The digests, 5' NMPs, were analyzed by 
two-dimensional TLC. The solvent system used for the first dimension 
was n-butyl alcohol/acetic acid/10% (v/v) acetic acid (66:32:2, by volume), 
and that used for the second dimension contained 0.1 m sodium phosphate 
(pH 6.8)/ammonium sulfate/1-propanol, 100:60:2 (v/v/v) (33).

Preparation of ADAR2* and PKR* MEF Cells—Mutant mouse 
line ADAR2* (GluR-B**R is an ADAR2* mouse line rescued by 
the introduction of a GluR-B allele containing an arginine codon for the 
Q/R site (34). MEF cells were prepared with E14.0 embryos derived 
from crosses of GluR-B**R mice (GluR-B**R allele was seen as 
cultured in Dulbecco's modified Eagle's medium with 10% fetal calf 
shear. All procedures involving mice were approved by the Wistar 
Institutional Animal Care and Use Committee.

In Vivo Silencing of EGFP by siRNA in MEF Cells—In vivo effects of 
ADAR1 on the siRNA-based RNA silencing of EGFP by 19-bp EGFP 
siRNAs were assayed in wild-type, ADAR1−/− (36), ADAR2−/− (GluR-
B**R, and PKR* MEF cells (see below), by using a dual fluorescence 
reporter system (37). MEF cells were cultured in Dulbecco's modified 
Eagle's medium supplemented with 10% fetal calf serum, trypsinized, 
and washed twice with phosphate-buffered saline prior to transfection. 
A transfection mixture of 1.5 μg each of pEGFP-C1 and pCMV-DEd-
Express reporter plasmids (Clontech) and a combination of EGFP 
siRNA and nonspecific control siRNA (total concentration adjusted to 
be equivalent to 10 nM) was electroporated into 106 MEF cells (36) at 
an electroporation buffer optimized for MEF cells and NucleofectorTM 
(Amaxa Biosystems, Cologne, Germany). For the rescue experiments, 3 
μg of pCMV-F-ADAR1p150, pCMV-F-ADAR1ΔMIM2M2, or pCMV/CMV 
(vector-only control) was also included in the transfection mixture. The 
dsRNA-binding domains mutant ΔMIM2M2 lacks all three dsRNA-
binding domains, as described previously (39). For transfection, the 
mixture including siRNA was added to 10 ml of the complete media. 
The specific siRNA concentration was indicated as the final concentrations 
in 10 ml of culture media (0–25 nm). The transient transfection 
efficiency was comparable between pEGFP-C1 and pCMV-DeRed-
Express plasmids (70–90%). The MEF cells transfected and continuously 
cultured with siRNA were harvested 44 h post-electroporation, 
trypsinized, washed with phosphate-buffered saline, suspended in 
chilled phosphate-buffered saline, and subjected to fluorescence-acti-
cated cell sorting (FACS) analysis using a FACS-flow cytometer (Da-
kocytomation, Carpinetia, CA). The relative levels of green (EGFP) 
and red fluorescence (RFP) for different samples were quantified by 
using the geometric means, and the normalized ratio of target (EGFP) 
to control (RFP) expression was determined at various concentrations 
of specific siRNA in the culture media. Data were analyzed using Summit 
Software (DakoCytomation).

Western Immunoblot Analysis—The total protein extracted from 
wild-type, ADAR1−/−, or ADAR1−/−− MEF cells transiently transfected 
with pCMV-F-ADAR1p150, pCMV-F-ADAR1ΔMIM2M2, or pCMV/CMV 
(vector-only control) plasmid DNA for 44 h was fractionated on an 
SDS-8% PAGE gel and analyzed by Western blotting using 
mAB M2 specific for FLAG epitope-tagged proteins. Various amounts 
of recombinant ADAR1p150 protein loaded onto the gel were used 
for calibration. Chemiluminescence intensity was recorded on film. 
The relative amount of ADAR1 protein was estimated by compar-

ing the integrated density of each chemiluminescence spot, measured 
with a flatbed scanning microdensitometer (model 1010G, PerkinElmer 
Life Sciences) using a 50 × 400-μm slit aperture.

duced by ADAR and PKR.
RESULTS

Specific and High Affinity Binding of siRNA by ADAR1p150—Because RNAi acts in the cytoplasm, the most relevant member of the ADAR gene family is ADAR1p150 (Fig. 1). Therefore, using an electrophoretic mobility shift assay (EMSA), we first tested binding of ADAR1p150 to a synthetic 21-nt siRNA, homologous to EGFP containing a double-stranded region of 19-bp and 2-nt 3' overhangs on both sense and antisense strands (19-bp EGFP siRNA). ADAR1p150 bound this EGFP siRNA very strongly with an apparent dissociation constant ($K_d$) of 0.21 nM (Fig. 2A and Table I). This unexpectedly high affinity is comparable with the affinity of p150 for a long, completely complementary dsRNA of 575 bp ($K_d = 0.12$ nM) (Table I). The $K_d$ value for two additional siRNAs that corresponded to different regions of the EGFP sequence as well as one siRNA unrelated to the EGFP sequence was identical to that for binding of the 19-bp EGFP siRNA, indicating a sequence-independent interaction (data not shown). Competitive inhibition assays indicated that binding of ADAR1p150 to siRNA is specific and is inhibited only by siRNA but not by the sense strand of siRNA or by a short dsDNA matching the sequence of the siRNA (Fig. 2B).

We assessed siRNA binding affinity in a separate experiment using a nitrocellulose filter-binding assay previously used to evaluate the binding of long dsRNA (32). The $K_d$ value measured in this assay was identical to the $K_d$ value measured with EMSA, confirming the strong binding of ADAR1p150 to siRNA (data not shown). Dissociation of the ADAR1p150-siRNA complex was then examined with the filter-binding assay. A binding reaction carried out with 5 nM ADAR1p150 was diluted 50-fold by adding binding buffer and continuously incubating for various times before filtering. The amount of ADAR1p150-siRNA complex was unaffected by the rapid reduction in siRNA and protein concentration for up to 2 h after dilution, revealing that the ADAR1p150-siRNA complex, once formed, is very stable (data not shown). These results indicate that the off-rate for dissociation of siRNA from the ADAR1p150-siRNA complex is $10^{-4}$ s$^{-1}$, consistent with binding affinity in the subnanomolar range.

![Fig. 1](image1.png)

**Fig. 1.** Three mammalian ADAR gene family members. Indicated are the Z$\alpha$ and Z$\beta$ Z-DNA-binding domains (ADAR1), the dsRNA-binding domains (dsRBD), the arginine-rich (R domain) sense strand of siRNA-binding domain (ADAR3), and the deaminase domain. aa, amino acids.

![Fig. 2](image2.png)

**Fig. 2.** High affinity binding of ADARs. A, binding of homodimeric ADAR1 and ADAR2 to siRNA. Varying concentrations of FLAG-tagged ADAR1p150 (0.05, 0.075, 0.1, 0.15, 0.2, 0.5, 1, 5, and 10 nM), ADAR1p110 (0.5, 1, 2, 10, 20, 50, and 100 nM), ADAR2 and ADAR3 (2.5, 5, 10, 15, 25, 50, 100, 250, and 500 nM) were examined by EMSA using a native 4% polyacrylamide gel. The 5’-end of the sense strand of 19-bp EGFP siRNA (10 pm) was labeled with $^{32}$P. The 5’-end of the antisense strand was also phosphorylated but without $^{32}$P. B, specificity of ADAR1 binding to siRNA. Competitive inhibition experiments were conducted by preincubating ADAR1p150 (5 nM) with varying concentrations of cold competitors (0, 0.05, 0.25, 0.75, and 1.5 nM) for 5 min prior to addition of $^{32}$P-labeled 19-bp siRNA probe (10 pm). siRNA, 19-bp EGFP siRNA; ssRNA, single-stranded RNA; the sense strand of the 19-bp EGFP siRNA; siDNA, dsDNA corresponding to the 19-bp EGFP siRNA.
ADAR1 RNA Editase Limits siRNAi Efficacy

**Table I**

| Binding affinity (Kd, nM) | ADARp150 | ADAR1E912A p150 | ADARp110 | ADAR2 | ADAR2E396A | ADAR3 |
|--------------------------|----------|-----------------|----------|-------|------------|-------|
| 575-bp dsRNA<sup>a</sup> | 0.12 ± 0.01 | 0.14 ± 0.02 | 0.24 ± 0.03 | 0.29 ± 0.06 | 0.34 ± 0.08 | 0.43 ± 0.03 |
| 36-bp siRNA<sup>a</sup> | 0.11 ± 0.01 | 0.32 ± 0.02 (−5)<sup>d</sup> | 2.6 ± 0.2 (−25<sup>c</sup>), (−50)<sup>c</sup> | 3.1 ± 0.5 (−50)<sup>d</sup> | 3.3 ± 0.3 (−50)<sup>d</sup> |
| 29-bp siRNA<sup>a</sup> | 0.11 ± 0.01 | 0.69 ± 0.10 | 3.1 ± 0.3 (−25<sup>c</sup>), (−50)<sup>c</sup> | 3.3 ± 0.3 (−50)<sup>d</sup> |
| 23-bp siRNA<sup>a</sup> | 0.12 ± 0.01 | 2.2 ± 0.2 | 1.9 ± 0.1 | 7.5 ± 0.3 |
| 19-bp siRNA<sup>a</sup> | 0.21 ± 0.02 | 0.3 ± 0.1 | 10 ± 1 |
| 15-bp siRNA<sup>a</sup> | 0.55 ± 0.03 | 4.1 ± 0.2 | 31 ± 2 |

<sup>a</sup> Kd values for siRNA (means ± S.E.) were estimated from the results of five independent EMSA experiments and are expressed in terms of the concentration of ADAR monomer, although all ADARs examined in the present study except ADAR3 are predominantly homodimer complexes.

<sup>b</sup> Kd values for this long dsRNA were obtained using the filter binding assay.

<sup>c</sup> Kd values for these two longer siRNAs represent an apparent dissociation constant for the first complex (fast migrating on EMSA gels).

<sup>d</sup> Approximate Kd values for the second complex (slow migrating) are indicated.

<sup>e</sup> Approximate Kd values for the third complex (slow migrating) are indicated.

<sup>f</sup> NB, no measurable binding by EMSA.

**Binding of Other ADARs and Effects of the siRNA Size—**

ADARp110 and ADAR2 also bound the 19-bp siRNA, but their binding affinities were 15 and 50 times lower than that of ADARp150, respectively; ADAR3 capable of binding long dsRNA failed to bind the 19-bp siRNA (Fig. 2A and Table I). Both ADAR1 and ADAR2 form a stable, enzymatically active homodimer complex, whereas ADAR3 remains monomeric (28).

Our previous studies suggested that homodimerization and interactions of the two monomers of ADAR1 or ADAR2 may play a critical role in the site-selective editing mechanism (28). Most interestingly, formation of the ADAR1- or ADAR2-siRNA complexes was quite sensitive to the salt concentration. For instance, formation of ADARp150-siRNA complexes decreased 10-fold when the NaCl concentration was raised from 0.1 to 0.5 M, possibly indicating also the importance of ionic interactions between the two monomers for binding of siRNA. In contrast, ADARp150 binding to long dsRNAs was essentially unaffected in the presence of 0.5 M NaCl, although the binding affinity for long dsRNAs diminished slightly in 1 M NaCl (data not shown). We also examined the E912A and E396A mutants of ADAR1 and ADAR2, respectively, which retain intact dsRNA-binding domains but lack a functional deaminase domain (thus catalytically dead) (28, 32) and also lack productive interactions between the two monomers in a homodimer complex (28). These mutants bound siRNA, although their binding affinity was substantially (2–10-fold) lower than that of the wild-type proteins (Table I). Their lower affinity for siRNAs may indicate once again the importance of the functional monomer interactions perturbed in these mutants in the siRNA binding.

We next examined binding to two different siRNAs with shorter or longer dsRNA regions (15 and 25 bp). All ADARs that were capable of binding the 19-bp siRNA (ADARp150 and p110 and ADAR2) also bound siRNAs containing either the 15- or 23-bp dsRNA regions, although shortening or lengthening of the dsRNA region in the siRNA affected the binding affinity (Table I). For instance, the binding affinity of ADARp150 or ADAR2 for the 15-bp siRNA was 3-fold weaker than that for the 19-bp siRNA (Table I). We also examined binding of ADARp150 to the 19-bp siRNA that lacked 2-nucleotide 3′-overhangs (blunt end). ADARp150 bound this blunt end siRNA, but the 2-nt 3′-overhangs of siRNA appeared to make an additional contribution to strong binding (e.g. ADARp150 binding to the 19-bp siRNA, Ks = 0.21 nM versus the 19-bp blunt end siRNA, Ks = 0.43 nM). A 5′ phosphate group of the antisense strand of siRNA is required for the RNAi mechanism (37, 38). However, high affinity binding of ADARp150 to siRNA appeared to be independent of 5′-end phosphorylation, because ADARp150 also bound strongly to siRNA consisting of a 5′-phosphorylated sense and nonphosphorylated antisense strand. Furthermore, siRNA with both strands nonphosphorylated at the 5′-end effectively competed with normal siRNA having both 5′-phosphorylated sense and antisense strands in a competitive inhibition assay (data not shown).

**A-to-I RNA Editing Independent Binding of siRNA—**

Because the mutants lacking deaminase activity (ADAR1E912A and ADAR2E396A) are capable of binding to siRNAs, complex formation of ADAR1 or ADAR2 with a typical 19-bp siRNA is independent of A-to-I RNA editing. Efficient A-to-I editing occurs with dsRNAs of ≥30 bp in length, although a very limited editing may occur with dsRNAs as short as 23 bp (39). In order to confirm A-to-I RNA editing independent binding of typical siRNAs, we tested the 19-bp EGFP siRNA as well as two additional siRNAs, containing a 29- and a 36-bp dsRNA region, for the A-to-I conversion reaction. Two-dimensional TLC analysis of mononucleotides derived from siRNAs complexed with wild-type ADARp150 revealed that low efficiency editing of adenosines (~10%) occurs in the 36- but not the 29- and 19-bp siRNAs (Fig. 3B). Identical results for siRNA bound to ADAR2 were obtained; low efficiency editing was only with 36-bp siRNA (not shown). These results confirm that the length of siRNA determines whether bound siRNA is edited or held in a stable complex without change of sequence; the critical size threshold appears to be ≥30 bp.

As expected, EMSA analysis revealed that both ADARp150 and ADAR2 bound these longer siRNAs. At low concentrations of protein, a single discrete siRNA-ADAR complex was detected (Fig. 3A). Their binding affinity was slightly higher than siRNAs with a shorter dsRNA region (Table I). However, as the ADAR concentration increased, formation of multiple complexes was noted during binding of 36-bp siRNA by ADARp150 and during binding of 29- and 36-bp siRNAs by ADAR2 (Fig. 3A). It appears that different siRNA-ADAR complexes were formed as the ratio of siRNA to protein changed. Formation of multiple complexes for these longer siRNAs was detected also with catalytically inactive ADARp150E912A and ADAR2E396A mutants, suggesting that formation of multiple complexes is unlikely to be due to editing of these longer siRNAs (Fig. 3A). A possible explanation for formation of multiple complexes is that they differ in the number of siRNA molecules bound to one ADAR homodimer, but currently available data cannot eliminate other possibilities (see “Discussion”).

**Enhanced Silencing by siRNA in ADAR1 Null Mutant Fibroblast Cells—**

To assess the in vivo effects of siRNA binding by ADARs, we compared the efficacy of siRNA-based gene silencing in mutant mouse embryonic fibroblasts (MEF) null for ADAR1 (35, 40) or ADAR2 (34) to that in wild-type cells (Fig. 4A). As an additional control, Pkr null MEF cells (35) were also tested. Expression of EGFP was targeted with 19-bp EGFP siRNA used for the in vitro binding EMSA analysis and as-
sayed with an in vivo dual fluorescence reporter system using pEGFP-C1 (target) and pCMV-DsRed-Express (control) plasmids. A control 19-bp siRNA with sequence unrelated to EGFP or RFP had no effects on the expression of EGFP and RFP at the highest concentration tested, in both wild-type and three separate mutant MEF cells (25 nM control 19-bp siRNA tested; see Fig. 4A, EGFP siRNA 0 nM control experiments). Although suppression of target EGFP expression by 10-fold was detected in wild-type and all mutant MEF cells at relatively high concentrations, substantially enhanced silencing effects (up to 3-fold) were detected in ADAR1−/− MEF cells at relatively low concentrations of siRNA. For instance, although EGFP expression was decreased only to 42–46% in wild-type, PKR−/−, or ADAR2−/− MEF cells by 1 nM EGFP siRNA, the expression was down-regulated to 16% in ADAR1−/− cells. The enhanced RNAi effects in ADAR1−/− MEF cells were confirmed with experiments using a different siRNA that corresponded to a different region of the EGFP sequence (data not shown).

In order to further demonstrate the in vivo suppressive effects of ADAR1, we examined silencing of the EGFP in ADAR1 null MEF cells transfected with a FLAG-tagged ADAR1p150 expression plasmid. The vector-only control and an additional mutant construct ADAR1ΔMIM2M3, in which all three dsRNA-binding domains were deleted (32), were also tested (Fig. 4B). These rescue experiments confirmed the quenching effects by the wild-type ADAR1 but not by the ΔMIM2M3 mutant or vector alone for siRNA mediated EGFP silencing. These results indicated also that the quenching activity of ADAR1 is likely to be exerted through siRNA binding by its dsRNA-binding domains.

Western analysis using M2 mAb specific for FLAG-tagged proteins detected roughly equal levels of wild-type ADAR1p150 or ΔMIM2M3 (130-kDa) proteins in transfected ADAR1 null MEF cells (Fig. 4C). In light of the quenching effects on siRNA efficacy by ADAR1p150, the concentration of recombinant p150 proteins expressed in these cells was determined based on the MEF volume of 2 p1 (41) and the known amount of purified recombinant p150 standard (Fig. 4C). We estimated that transfected ADAR1 null MEF cells contained ∼1 nM ADAR1p150, sufficient for quenching 0.5–1 nM siRNA. Taken together, our results indicate that ADAR1

![Fig. 3. A-to-I editing of 36-bp but not 29- or 19-bp siRNA. A, ADAR1p150 (wild-type and E912A mutant) and ADAR2 (wild-type and E396A mutant) were tested for binding at 30 °C for 60 min to 29- or 36-bp siRNA (10 pm), and the reaction products were analyzed by EMSA. ADAR1p150, 0.05, 0.075, 0.1, 0.15, 0.2, 0.5, 1, 5, and 10 nM ADAR2, 1, 2, 2.5, 5, 10, 20, 50, 100, and 250 nM. B, TLC analysis of siRNAs bound by ADAR1p150. Varying sizes of siRNA complexed with ADAR1p150 (wild-type) were analyzed for A-to-I editing of internal adenosine residues.](http://www.jbc.org/content/jbc/3950/3950F3A)

![Fig. 3. A-to-I editing of 36-bp but not 29- or 19-bp siRNA. A, ADAR1p150 (wild-type and E912A mutant) and ADAR2 (wild-type and E396A mutant) were tested for binding at 30 °C for 60 min to 29- or 36-bp siRNA (10 pm), and the reaction products were analyzed by EMSA. ADAR1p150, 0.05, 0.075, 0.1, 0.15, 0.2, 0.5, 1, 5, and 10 nM ADAR2, 1, 2, 2.5, 5, 10, 20, 50, 100, and 250 nM. B, TLC analysis of siRNAs bound by ADAR1p150. Varying sizes of siRNA complexed with ADAR1p150 (wild-type) were analyzed for A-to-I editing of internal adenosine residues.](http://www.jbc.org/content/jbc/3950/3950F3B)
Although RNAi is an extremely powerful gene silencing mechanism, certain cellular and viral factors appear to suppress its efficacy. For instance, ERI-1 is a ribonuclease that limits the efficacy of the endogenous RNAi mechanism by degrading specifically siRNAs (42). In contrast, a 19-kDa protein (p19) homodimer synthesized by tombusvirus, although incapable of binding long dsRNA, binds specifically siRNAs of a defined length (optimal binding at 19–21 bp) with a subnanomolar dissociation constant, thereby suppressing the host plant defense RNAi mechanism (43, 44). It is widely accepted that there are distinctive features of the mammalian RNAi pathway, such as a requirement for higher siRNA concentrations and relatively short lasting effects, possibly due to the lack of RNA-directed RNA polymerase-mediated amplification of siRNA (4, 5, 45). In addition, there may be certain cellular factors similar to ERI-1 and p19 that limit RNAi efficacy in mammals.

Double-strandedness of the trigger RNA is critical for RNAi. Thus, the potential for ADAR-mediated A-to-I editing of trigger dsRNAs and consequent dampening of RNAi efficacy has been pointed out previously (6, 31). As expected, A-to-I editing of a trigger dsRNA in vitro by recombinant ADAR2 greatly reduces the amount of siRNA produced and consequently antagonizes RNAi effects (29). In C. elegans homozygous for null mutations of both c.e.ADAR1 and c.e.ADAR2, transgenes are very effectively silenced through the RNAi mechanism. However, in wild-type worms, transgenes escape silencing because of A-to-I editing of their dsRNA transcripts, presumably derived from simultaneous transcription of the sense and antisense strands (30). These previous studies indicate that ADAR certainly can affect RNAi efficacy through A-to-I editing of trigger dsRNA (29, 30). In the present study, we investigated the interaction between ADAR gene family members and a series of synthetic siRNAs. Our studies revealed that ADAR1p150 bound to 19-bp siRNA, despite its short dsRNA region, with extremely high affinity. Furthermore, siRNA-based RNAi was substantially more effective in mouse fibroblasts homozygous for an ADAR1 null mutation than in wild-type cells. The suppressive effects of ADAR1 were confirmed in ADAR1 null cells when transfected with the ADAR1p150 expression plasmid but not when transfected with a mutant construct lacking dsRNA-binding domains. Our results identify ADAR1 as a cellular factor that limits the efficacy of siRNA in mammalian cells through an unexpected direct interaction with siRNA, in addition to the known effects on trigger dsRNA.

Importance of ADAR Homodimerization for Its Interaction with siRNA—Although the binding of most proteins recognizing A-form dsRNA is sequence-independent, their affinities and the minimum required lengths of target dsRNA appear to differ substantially. For instance, DICER binds long dsRNAs efficiently but not the resulting cleavage product siRNAs (46), whereas the dsRNA-binding domains of PKR (induced by interferons in the cytoplasm) bind 20-bp dsRNA but with relatively low affinity, Kd value of 170 nM (47). Although the co-crystal structure of a monomeric dsRNA-binding domain complexed with dsRNA suggested that a minimum of 16 bp of dsRNA may be sufficient for interaction (48), very little, if any, A-to-I editing of the 23-bp blunt end dsRNA by ADAR1 was detected in our previous studies, indicating that the shortest dsRNA recognized as a substrate for editing by ADAR1 might be ≥30 bp (39). Therefore, it is surprising to find that both ADAR1 and ADAR2 can bind typical siRNAs containing a 19-bp dsRNA region, as well as siRNAs containing an even shorter 15-bp dsRNA region. Most interestingly, the binding affinity of ADAR1p150 for siRNAs with 2-nt 3’overhangs is

(most likely cytoplasmic p150) reduces siRNA potency in vivo, probably by binding, thus decreasing the effective siRNA concentration.

**DISCUSSION**

**FIG. 4. Suppression of siRNA-based RNAi by ADAR1.** A, effects of endogenous ADAR1 proteins. A combination of varying concentrations of 19-bp EGFP siRNA and nonspecific control siRNA together with pEGFP-C1 target (1.5 μg) and pCMV-DsRed-Express control (1.5 μg) plasmid DNA were co-transfected into wild-type, PKR null, ADAR2 null, and ADAR1 null MEF cells. Quantitative measurement of EGFP and RFP expression levels were done by FACS analysis, and the EGFP expression level relative to that of RFP was determined. Results are presented as means ± S.E. (bars) values of five independent experiments performed in triplicate. The reduction in the relative EGFP expression levels in ADAR1 null MEF cells was examined statistically by individual unpaired Student’s t tests in comparison to those in wild-type, PKR null, and ADAR2 null MEF cells. p < 0.001 for both 0.5 and 1 nM concentrations. B, effects of recombinant ADAR1p150 proteins. In addition to pEGFP-C1 and pCMV-DsRed-Express, 3.0 μg of pCMV-F-ADAR1p150 or pCMV-F-ADAR1ΔM1M2M3 were transfected into ADAR1 null MEF cells. The vector-only control experiments were also conducted with pR/CMV plasmid DNA. Results are presented as the mean ± S.E. (bars) values from three independent experiments performed in triplicate. The difference between the vector-only control or pCMV-F-ADAR1ΔM1M2M3 experiments and the pCMV-F-ADAR1p150 experiments (0.5, 1.0, and 2.0 nM concentrations) were significant (p < 0.001) by unpaired Student’s t tests. C, the total protein extracted from 1 × 106 ADAR1 null MEF cells transfected for 44 h with vector-only (lane 3), pCMV-F-ADAR1p150 (lane 4), or pCMV-F-ADAR1ΔM1M2M3 (lane 5), together with varying amounts of FLAG epitope-tagged p150 standard proteins (0.5 or 2 fmol) was examined by Western blotting analysis.
slightly higher (~2-fold) than that of blunt end dsRNAs, indicating an additional contribution of the overhangs to the high affinity binding.

ADAR1 and ADAR2 are homodimers, whereas ADAR3, which is incapable of binding siRNAs, is a monomer (28). All three ADARs do bind long dsRNAs equally well (32). Furthermore, the siRNA binding affinity of ADAR1p150E912A and ADAR2E396A, two catalytically inactive mutants, is substantially lower than that of wild-type proteins. The decreased binding affinity of these mutant homodimeric forms is perhaps due to diminished functional interactions between their two monomers, a consequence of the role played by the mutated glutamate residue in formation of the dimer interface (28).

Thus, one possible reason that ADAR1 and ADAR2 bind to short dsRNAs, such as siRNAs, is that their homodimeric configuration allows short dsRNAs to interact with more than one dsRNA-binding domain of the two monomers (Fig. 5A).

The siRNA binding curve (ADAR-siRNA complex versus ADAR concentration) is sigmoidal and steeper than a normal single-site saturation curve at low ADAR concentrations, indicating that multiple binding sites present on a single molecule interact with positive cooperativity to give the observed high affinity binding. The curve is consistent with all sites being equivalent (i.e. having the same intrinsic binding constant), but of course more complicated models would also fit the data. Formation of multiple complexes is detected for binding of longer siRNAs (29 or 36 bp). A single discrete band is seen on the gel at low concentrations of ADAR. As the protein concentration increases, other bands appear, representing complexes with lower affinity. Once again, a reasonable interpretation is that the lower apparent affinity is the result of less cooperative enhancement of the intrinsic single-site affinity due to under-saturation of the multiple sites on each ADAR homodimer molecule (Fig. 5A). Obviously, a complete analysis of the equilibrium among multiple interacting sites requires much more precise data than can be obtained from our EMSA gels.

Effects of Z-DNA Binding Domains on siRNA Binding—In view of their similar affinity for long dsRNAs, the substantial differences in siRNA binding affinity between ADAR1p150, ADAR1p110, and ADAR2 are surprising. The binding affinity of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2. The difference detected in the binding affinities of ADAR1p150 to the 19-bp siRNA was 50-fold greater than that of ADAR2.
within p110 (Fig. 1), efficient binding of ADAR1 to Z-DNA requires both Za and Zβ (49). The function of these two Z-DNA-binding domains, which are apparently dispensable for A-to-I editing of long dsRNA substrates (50), has been a subject of speculation (49). Our results suggest that one function of the Za domain of ADAR1p150 may be to mediate high affinity binding to siRNAs. Because ADAR2 can bind siRNAs, despite lacking the Z-DNA-binding domains, direct binding of siRNAs to these domains is unlikely. However, the Za domain may contribute to the extremely strong binding of ADAR1p150 to siRNAs via its effects on the neighboring dsRNA-binding domains and/or on interactions between monomers. The nuclear export of ADAR1p150 into the cytoplasm, mediated by the nuclear export receptor CMR1 which forms an export-competing complex together with RanGTP, has been reported to be dependent on the Za domain (51). It is of special interest that the Za domain is also essential for the high affinity binding of ADAR1p150 to siRNAs. Its presence in ADAR1p150 may be indicative of the specific function of ADAR1p150 in dealing with this type of short dsRNA substrate that localizes to the cytoplasm.

**Implication of the ADAR1p150-siRNA Interaction for RNAi Efficacy**—Fragmentation of long trigger dsRNAs to siRNAs is carried out by DICER in the cytoplasm (4, 5). Moreover, recent studies (52, 53) using DNA microarrays indicate that not only long dsRNA but also siRNA activate the interferon pathway in contrast to widely accepted assumptions. Thus, the interaction of siRNAs with ADAR1p150, the only interferon-inducible and cytoplasmically localized ADAR gene family member (24, 25), is likely to have the most significant effects on siRNA-based RNAi. Indeed in *vivo* targeting of EGFP by siRNA is more efficient in fibroblast cells homozygous for an ADAR1 null RNAi complex, which decreases the concentration of siRNA targeting of EGFP by siRNA is more efficient in fibroblast cells homozygous for an ADAR1 null RNAi complex, which decreases the concentration of siRNA...
